Biosimilars: Company Strategies to Capture Value from the Biologics Market
نویسندگان
چکیده
Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to enter the biosimilars market: research and development, manufacturing, supporting activities, marketing, and lobbying. Understanding the importance of each of these capabilities will be key to maximising the value generated from the biologics patent cliff.
منابع مشابه
The economics of biosimilars.
BACKGROUND The high cost of pharmaceuticals, especially biologics, has become an important issue in the battle to control healthcare costs. The Hatch-Waxman Act encourages generic competition but still provides incentives for pioneers to develop new drugs. The Biologics Price Competition and Innovation Act is intended to do the same for biologics and biosimilars. OBJECTIVE To examine informat...
متن کاملOATP1A2 and P-gp expression level dependent transport of zolmitriptan and fexofenadine across MDCKII monolayers
Outsourcing and Standardization of Global Studies Joseph F. Bower Ph.D., MBA Covance Laboratories, Inc. The global biologics drug market continues to expand and increase its portion of the global pharmaceutical market. While biologics only accounted for 15% of the global pharmaceutical market’s revenue in 2012; the top three drugs in 2012 were all biologics. This portion will rapidly increase a...
متن کاملRegulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
In March 2010 Congress established an abbreviated Food and Drug Administration approval pathway for biosimilars-drugs that are very similar but not identical to a reference biological product and cost less. Because bringing biosimilars to the market currently requires large investments of money, fewer biosimilars are expected to enter the biologics market than has been the case with generic dru...
متن کاملBiomedical and Market Issues Surrounding the Advent of Biosimilars
As the patents associated with the biologics are set to expire in the near future, a new type of therapy appears on the horizon, and it is quite similar to the biologics. This commentary examines the biomedical and market issues surrounding the advent of biosimilars.
متن کاملBiosimilars: An Emerging Category of Biologic Drugs for Emergency Medicine Practitioners
Biologics are the fastest growing segment of annual United States (US) drug expenditure. Biologics are complex proteins derived from living sources that are important therapy for a variety of diseases. The US is now poised to introduce biosimilars, which are copies of biologics that are not manufactured by the innovator company and are approved under an abbreviated regulatory process. Biosimila...
متن کامل